此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung Cancer

2016年6月13日 更新者:Nasser Hanna, M.D.

A Phase II Trial of Concurrent Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib in Patients With Inoperable Stage III Non-Small Cell Lung Cancer (NSCLC): Hoosier Oncology Group LUN06-107

Sorafenib has demonstrated in vivo anti-tumor efficacy. This trial will evaluate the safety and preliminary efficacy of sorafenib following chemoradiation in locally advanced NSCLC.

研究概览

详细说明

Outline: This is a multi-center study.

Chemotherapy/radiation therapy (2 cycles)

  • Cisplatin 50 mg/m2 IV days 1 and 8 of 28 day cycle
  • Etoposide 50 mg/m2 IV days 1-5 of 28 day cycle
  • Concurrent chest radiation (planned dose is 5940 cGy with an additional, optional boost of 1080 cGy to a total allowed dose of 7020 cGy) with the following:

Maintenance therapy of Sorafenib 400 mg PO BID of 28 day cycle, to begin a minimum of 6 and maximum of 9 weeks from completion of chemo-radiotherapy until PD, intolerable toxicity, or up to 1 year.

Patients with progressive disease will discontinue treatment.

ECOG performance status 0 or 1

Hematopoietic:

  • Absolute neutrophil count (ANC) ≥ 1500 mm3
  • Platelet count ≥ 100,000 mm3
  • Hemoglobin ≥ 9 g/dL
  • PT or INR < 1.5 x ULN unless on anti-coagulant therapy
  • PTT < 1.5 x ULN unless on anti-coagulant therapy

Hepatic:

  • Bilirubin ≤ 1.5 x ULN
  • ALT ≤ 2.5 x ULN (≤ 5 x ULN for patients with liver involvement)
  • AST ≤ 2.5 x ULN (≤ 5 x ULN for patients with liver involvement)

Renal:

  • Creatinine < 1.5 X upper limit of normal (ULN)

Cardiovascular:

  • No significant history of cardiac disease: Congestive heart failure > class II NYHA.
  • Patients must not have unstable angina (anginal symptoms at rest) or new onset angina (began within 90 days prior to registration for initial therapy) or myocardial infarction within 6 months prior to registration for initial therapy.

Respiratory:

  • FEV1 ≥ 1 liter by spirometry within 60 days prior to registration for initial therapy.

研究类型

介入性

注册 (实际的)

8

阶段

  • 阶段2
  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Illinois
      • Galesburg、Illinois、美国、61401
        • Medical & Surgical Specialists, LLC
    • Indiana
      • Fort Wayne、Indiana、美国、46815
        • Fort Wayne Oncology & Hematology, Inc
      • Goshen、Indiana、美国、46527
        • Center for Cancer Care at Goshen Health System
      • Indianapolis、Indiana、美国、46202
        • Indiana University Cancer Center
      • Lafayette、Indiana、美国、47905
        • Horizon Oncology Center
      • Muncie、Indiana、美国、47303
        • Medical Consultants, P.C.
      • South Bend、Indiana、美国、46601
        • Northern Indiana Cancer Research Consortium
    • Ohio
      • Cincinnati、Ohio、美国、45247
        • Oncology Partners Network

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Histological or cytological proof of non-small cell lung cancer (NSCLC).
  • Measurable or non-measurable disease per RECIST.
  • Unresectable Stage IIIA or IIIB disease as evaluated by imaging.
  • Must be age ≥ 18 years at the time of consent.
  • Written informed consent and HIPAA authorization for release of personal health information.
  • Females of childbearing potential and males must be willing to use an effective method of contraception.
  • Females of childbearing potential must have a negative pregnancy test within 7 days prior to being registered for initial therapy.

Exclusion Criteria:

  • No prior chemotherapy or radiotherapy for lung cancer.
  • No positive supraclavicular or scalene lymph nodes extending up into the cervical region.
  • No superior sulcus (pancoast tumors).
  • No malignant pleural effusions. The only exception is a patient with a pleural effusion visible only on CT scan (and not visible on CXR) OR deemed too small to tap.
  • No clinically significant or malignant pericardial effusions.
  • No CNS metastases.
  • No unintended weight loss (> 5% body weight) in the preceding 90 days prior to registration for initial therapy.
  • No treatment with any investigational agent within 30 days prior to being registered for initial therapy.
  • No prior therapy with a Ras pathway inhibitor or anti-angiogenic agent.
  • No other active cancers.
  • Females must not be breastfeeding.
  • No active clinically serious infections as judged by the treating investigator (> CTC v3, Grade 2) including known human immunodeficiency virus (HIV) infection or chronic Hepatitis B or C.
  • No major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to registration for initial therapy.
  • No anticipation of need for major surgical procedure during the course of the study.
  • No minor surgical procedures such as fine needle aspirations or cone biopsies within 7 days prior to registration for initial therapy.
  • No history of allergic reactions to drugs utilizing the vehicle polysorbate 80 + polyethylene glycol (etoposide).
  • No history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to registration for initial therapy.
  • No use inhibitors or inducers of the cytochrome p450 system CYP3A4 enzyme or other medications such as aprepitant, ketoconazole, itraconazole, quinidine, digoxin, cyclosporine, ritonavir, grapefruit products, St. John's Wort, rifampin (rifampicin), carbamazepine, phenytoin, dexamethasone, and phenobarbital.
  • No evidence or history of bleeding diathesis or coagulopathy.
  • No serious non-healing wound, ulcer, or bone fracture.
  • No known or suspected allergy to sorafenib.
  • No uncontrolled hypertension defined as systolic blood pressure > 150 mm Hg or diastolic pressure > 90 mm Hg, despite optimal medical management.
  • No thrombolic or embolic events such as a cerebrovascular accident including transient ischemic attacks within 6 months prior to registration for initial therapy.
  • No pulmonary hemorrhage/bleeding event ≥ CTCAE Grade 2 within 4 weeks prior to registration for initial therapy.
  • No hemorrhage/bleeding event ≥ CTCAE Grade 3 within 4 weeks prior to registration for initial therapy.
  • No condition that impairs patient's ability to swallow whole pills or any malabsorption problem.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Investigational Treatment
Cisplatin/Etoposide/Radiotherapy followed by Sorafenib in patients with inoperable stage III non-small cell lung cancer
Cisplatin 50 mg/m2 IV, days 1 and 8 of 28 day cycle
Etoposide 50 mg/m2 IV, days 1-5 of 28 day cycle
Concurrent chest radiation (planned dose is 5940 cGy with an additional, optional boost of 1080 cGy to a total allowed dose of 7020 cGy)
Maintenance therapy of Sorafenib 400 mg PO BID, to begin a minimum of 6 and maximum of 9 weeks from completion of chemo-radiotherapy until PD, intolerable toxicity, or up to 6 months

研究衡量的是什么?

主要结果指标

结果测量
大体时间
Time to Disease Progression (TTP)
大体时间:18 months
18 months

次要结果测量

结果测量
大体时间
总生存期
大体时间:18个月
18个月

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 学习椅:Nasser Hanna, M.D.、Hoosier Oncology Group, LLC

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2007年6月1日

初级完成 (实际的)

2008年4月1日

研究完成 (实际的)

2008年4月1日

研究注册日期

首次提交

2006年12月28日

首先提交符合 QC 标准的

2006年12月28日

首次发布 (估计)

2006年12月29日

研究记录更新

最后更新发布 (估计)

2016年7月25日

上次提交的符合 QC 标准的更新

2016年6月13日

最后验证

2016年5月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅